Immunocore Holdings Plc Stock Price, News & Analysis

Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.

Immunocore Holdings plc (Nasdaq: IMCR) is a commercial-stage biotechnology company focused on T cell receptor (TCR) bispecific immunotherapies for cancer, infectious diseases and autoimmune diseases. News about Immunocore frequently centers on the commercial performance and clinical development of its lead product, KIMMTRAK, which is approved for HLA‑A*02:01‑positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, and on its broader melanoma franchise.

Investors following IMCR news can expect regular updates on Phase 3 oncology trials, including the TEBE‑AM registrational trial of tebentafusp in second‑line or later advanced cutaneous melanoma, the ATOM adjuvant uveal melanoma trial, and the PRISM‑MEL‑301 trial evaluating brenetafusp plus nivolumab in first‑line advanced cutaneous melanoma. Company press releases also describe progress in Phase 1/2 studies of PRAME‑targeting ImmTAC candidates across ovarian cancer, non‑small cell lung cancer and other solid tumors.

Beyond oncology, Immunocore issues news on its ImmTAV infectious disease programs, such as IMC‑M113V for people living with HIV and IMC‑I109V for chronic hepatitis B infection, including early clinical data on safety, pharmacodynamic effects and viral antigen reductions. Updates on ImmTAAI candidates for autoimmune conditions, including type 1 diabetes and inflammatory dermatological diseases, are also part of the company’s communications.

This IMCR news page aggregates company press releases, conference participation announcements and SEC‑related disclosures, giving readers a single view of developments in KIMMTRAK commercialization, pipeline milestones, trial readouts and strategic priorities across oncology, infectious disease and autoimmune pipelines.